GQ-16 – 5 mg

Brand:
Cayman
CAS:
870554-67-9
Storage:
-20
UN-No:
De Minimis - 3077 / 9

Full activation of peroxisome proliferator-activated receptor γ (PPARγ), e.g., using thiazolidinediones, effectively treats insulin resistance and type 2 diabetes but also commonly promotes weight gain, hyperphagia, and edema.{21030} GQ-16 is a partial agonist for PPARγ (Ki = 160 nM) which induces adipogenesis significantly less than the full activator rosiglitazone.{21030} Like rosiglitazone, GQ-16 reverses high fat diet-mediated impairments in insulin signaling.{21030} However, GQ-16 does not induce weight gain, hyperphagia, or edema. GQ-16 does not activate PPARα, PPARβ/δ, or RXRα.{21030}  

 

Available on backorder

SKU: 11908 - 5 mg Category:

Description

A partial agonist for PPARγ (Ki = 160 nM) which induces adipogenesis significantly less than the full activator rosiglitazone; reverses high fat diet-mediated impairments in insulin signaling; does not induce weight gain, hyperphagia, or edema; does not activate PPARα, PPARβ/δ, or RXRα


Formal name: 5Z-[(5-bromo-2-methoxyphenyl)methylene]-3-[(4-methylphenyl)methyl]-2,4-thiazolidinedione

Synonyms: 

Molecular weight: 418.3

CAS: 870554-67-9

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Receptor Pharmacology|Agonists||Research Area|Endocrinology & Metabolism|Hormones & Receptors|PPARs||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes